文献速递临床免疫分子诊断

急性SARS-CoV-2感染中S1、S2和NCP特异性IgM、IgA和IgG抗体动力学:微阵列与十二种其他免疫测定法的评估

Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
PubMed 文献 · J Clin Microbiol · 2021-04-20

结果显示NCP特异性IgA和IgG在急性期检出率更高,S1特异性IgG峰值更高;不同商业免疫测定法的敏感性差异仅部分与靶抗原相关。

要点

  • NCP特异性IgA和IgG抗体在急性COVID-19期间检出率持续高于S1和S2特异性抗体
  • S1特异性IgG抗体峰值水平更高,且重症患者S1特异性IgG和IgA水平更高
  • 商业免疫测定法敏感性差异仅部分与靶抗原相关,不同试剂间敏感性和特异性存在差异

核心结论

  • 急性SARS-CoV-2感染期间商业免疫测定法的敏感性差异仅部分与靶抗原相关。
  • NCP特异性IgA和IgG抗体检测更早,重症患者S1特异性IgA抗体水平更高。

研究设计与样本

  • 使用微阵列、11种ELISA/CLIA和1种快速检测法(来自7家制造商)定量S1、S2和NCP特异性IgM、IgA、IgG及总Ig抗体。
  • 在130例非COVID-19肺炎患者中评估检测特异性。

主要发现

  • 微阵列检测显示NCP特异性IgA和IgG在急性COVID-19期间检出率持续高于S1和S2特异性抗体。
  • S1特异性IgG抗体达到更高峰值。
  • 症状出现后第26天前,所有患者均产生针对S1、S2和NCP的IgG应答。
  • ELISA/CLIA检出率与微阵列大致相似(对应靶抗原),但所有检测的敏感性和特异性存在差异。
  • 重症患者IgG和IgA水平更高,差异主要见于S1特异性免疫测定。

临床怎么用

  • 急性期SARS-CoV-2感染免疫测定选择时需考虑靶抗原和试剂性能差异,NCP特异性IgA/IgG可能更早检出。
  • 重症患者可关注S1特异性IgA和IgG水平升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this study, we comprehensively analyzed multispecific antibody kinetics of different immunoglobulins in hospitalized patients with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Three hundred fifty-four blood samples longitudinally obtained from 81 IgG-seroconverting progressed coronavirus disease 2019 (CoVID-19) patients were quantified for spike 1 (S1), S2, and nucleocapsid protein (NCP)-specific IgM, IgA, IgG, and total Ig antibodies using a microarray, 11 different enzyme-linked immunosorbent assays (ELISAs)/chemiluminescence immunoassays (CLIAs), and 1 rapid test by seven manufacturers. The assays' specificity was assessed in 130 non-CoVID-19 pneumonia patients. Using the microarray, NCP-specific IgA and IgG antibodies continuously displayed higher detection rates during acute CoVID-19 than S1- and S2-specific ones. S1-specific IgG antibodies, however, reached higher peak values. Until the 26th day post-symptom onset, all patients developed IgG responses against S1, S2, and NCP. Although detection rates by ELISAs/CLIAs generally resembled those of the microarray, corresponding to the target antigen, sensitivities and specificities varied among all tests. Notably, patients with more severe CoVID-19 displayed higher IgG and IgA levels, but this difference was mainly observed with S1-specific immunoassays. In patients with high SARS-CoV-2 levels in the lower respiratory tract, we observed high detection rates of IgG and total Ig immunoassays with a particular rise of S1-specific IgG antibodies when viral concentrations in the tracheal aspirate subsequently declined over time. In summary, our study demonstrates that differences in sensitivity among commercial immunoassays during acute SARS-CoV-2 infection are only partly related to the target antigen. Importantly, our data indicate that NCP-specific IgA and IgG antibodies are detected earlier, while higher S1-specific IgA antibody levels occur in severely ill patients.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Semmler G, Traugott MT, Graninger M, et al. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. J Clin Microbiol. 2021. PMID: 33602698. doi:10.1128/JCM.02890-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。